The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Following the success of immune checkpoint blockers (ICBs) in different cancer types, a
large number of studies are currently investigating ICBs in patients with hepatocellular …

Hepatocellular carcinoma (HCC) can have viral or non-viral causes,,,–. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …

Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …

Importance For more than a decade, sorafenib has been the only systemic treatment option
for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over …

Embolization with microspheres is a therapeutic strategy based on the selective occlusion of
the blood vessels feeding a tumor. This procedure is intraarterially performed in the clinical …

Systemic therapy for advanced hepatocellular carcinoma has expanded at an
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …

Immune checkpoint inhibitors (ICIs) with nivolumab and pembrolizumab are promising
agents for advanced hepatocellular carcinoma (HCC) but lack of effective biomarkers. We …

Importance Hyperprogressive disease (HPD) is a recognized pattern of rapid tumor
progression during immune checkpoint inhibitor (ICI) treatment. Definitions of HPD have not …

The introduction of immunotherapies has been a major development in the treatment of
many advanced cancers, including hepatocellular carcinoma (HCC). We are entering a new …